New chemotherapeutic agents for the treatment of non-small cell lung cancer: The Japanese experience

Chest

Volumn 113, Issue 1 SUPPL., 1998, Pages

  Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 HYDROXYSTAUROSPORINE; 7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOCETAXEL; ETOPOSIDE; EXATECAN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ANOREXIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESEARCH; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LUNG NON SMALL CELL CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ALKALOIDS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; GLUCOSIDES; HUMANS; JAPAN; LUNG NEOPLASMS; MITOMYCIN; MITOMYCINS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PURINE NUCLEOSIDES; STAUROSPORINE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0031965431     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Figures on cancer in Japan-1995. Tokyo: Foundation for Promotion of Cancer Research, 1995
2. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8:1301-09
3. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342:19-21
4. Edelman MJ, Grandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996; 37:385-93
5. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50:1715-20
6. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990; 50:5919-24
7. Kubota N, Kanzawa F, Nishio K, et al. Detection of topoisomerase 1 gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 1992; 188: 571-77
8. Matsuzaki T, Yokokura T, Mutai M, et al. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 1988; 21:308-12
9. Rothenberg ML, Kuhn JG, Burris HA, et al. Phase I and pharmacokinetic trial of Weekly CPT-11. J Clin Oncol 1993; 11:2194-2204
10. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-( 1-piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks. Cancer Res 1994; 54:427-36
11. Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann NY Acad Sci 1996; 803:292-305
12. Saijo N, Nishio K, Kubota N, et al. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol 1994; 34(suppl):S112-17
13. Sasaki Y, Hakusui H, Mizuno S, et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86:101-10
14. Sasaki Y, Mizuno S, Fujii H, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995; 86:117-23
15. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86:1096-98
16. Sasaki Y, Yoshida Y, Sudoh K, et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995; 86:111-16
17. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83:1164-68
18. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84:972-74
19. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990; 17:115-20
20. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-49
21. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210-21
22. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31:1283-87
23. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8:1907-12
24. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11:909-13
25. Society of Japanese Pharmacoponia. Summary basis of approval (SBA) No. 1 irinotecan hydrochloride (Campto injection, Topotecin injection). Tokyo: Yakuji Nippo, 1995
26. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukemia-lymphoma irinotecan hydrochloride (CPT-11). Br J Cancer 1994; 70:771-74
27. Yamamoto N, Tamura T, Karato A, et al. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the bayesian method in patients with lung cancer. Jpn J Cancer Res 1994; 85:972-77
28. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10:16-20
29. Kudoh S, Fukuoka M, Masuda N, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995; 86:406-13
30. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991; 18:607-12
31. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18:1013-19
32. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1992; 10:1225-29
33. Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56:789-93
34. Fukuoka M, Masuda M. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994; 34(suppl):S105-11
35. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994; 12:90-96
36. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68:777-82
37. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992; 10:1775-80
38. Nakagawa K, Fukuoka M, Niitani H, et al. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12:335
39. Shinkai T, Arioka H, Kunikane H, et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54:2636-42
40. Fujiwara Y, Yamakido M, Fukuoka M, et al. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1994; 13:335
41. Kudoh S, Kurihara N, Fukuoka M, et al. A phase II study of irinotecan combined with cisplatin in patients with small cell lung cancer [abstract]. Proc Jpn Soc Chest Dis 1995; 33:272
42. Karato A, Sasaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11:2030-35
43. Ando M, Eguchi K, Shinkai T, et al. Phase I study of sequentially administered CPT-11 and VP-16 for metastatic non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15:1522
44. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12:1833-41
45. Goto K, Nishiwaki Y, Saijo N, et al. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial [abstract]. Proc Am Soc Clin Oncol 1995; 14:362
46. Oshita F, Noda K, Nishiwaki Y, et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer. J Clin Oncol 1997; 15:304-09
47. Okishio K, Kudoh S, Kurihara N, et al. Irinoteean (CPT-11) enhances the radiosensitivity of lung cancer in vitro [abstract]. Proc Am Soc Clin Oncol 1995; 14:362
48. Yokoyama A, Kurita Y, Saijo N, et al. Phase I-II study of irinotecan (CPT-11) and cisplatin plus concurrent thoracic radiation therapy in stage III non-small cell lung cancer: a Japanese Clinical Oncology Group [abstract]. Proc Am Soc Clin Oncol 1996; 15:1242
49. Tamura T, Sasaki Y, Eguchi K, et al. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res 1994; 85:1057-62
50. Eisenhauer EA, Huinink WWB, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-66
51. Tamura T, Sasaki Y, Nishiwaki Y, et al. Phase I study of paclitaxel by 3-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 1995; 86:1203-09
52. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995; 1:599-606
53. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-94
54. Murphy WK, Fossella F, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-88
55. Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of paclitaxel in non-small cell lung cancer. Clin Cancer Res 1996; 2:941-45
56. Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995; 22:7-12
57. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel by 24 or 1 hour infusion in combination with carboplatin for advanced non-small cell lung cancer: the Fox Chase cancer experience. Semin Oncol 1995; 22:18-29
58. Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP56976 (docetaxel), a new anticancer drug. Jpn J Cancer Chemother 1994; 21:1997-2005
59. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12:1232-37
60. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75:968-72
61. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70:384-87
62. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238-44
63. Kudo S, Hino M, Fujita A, et al. Late phase II clinical study of RP 56976 (docetaxel) in patients with non-small cell lung cancer. Jpn J Cancer Chemother 1994; 21:2617-23
64. Yokoyama A, Kurita Y, Watanabe K, et al. Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Jpn J Cancer Chemother 1994; 21:2609-16
65. Coltman CA, Vinorelbine (Navelbine) - a new agent for the treatment of non-small cell lung cancer: a summary. Semin Oncol 1994; 21:1-3
66. Niitani H, Furuse K, Fukuoka M, et al. Phase I clinical study of new vinca alkaloid derivative, KW-2307 (vinorelbine). Jpn J Cancer Chemother 1994; 21:177-87
67. Furuse K, Kinuwaki E, Motomiya M, et al. Late phase II clinical study of KW-2307 in previously untreated patients with non-small cell lung cancer. Jpn J Cancer Chemother 1994; 21:1941-47
68. Furuse K, Ohta M, Fukuoka M, et al. Early phase II clinical study of KW-2307 in patients with lung cancer. Jpn J Cancer Chemother 1994; 21:785-93
69. Furuse K, Yamori S, Negoro S, et al. A late phase II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Jpn J Cancer Chemother 1995; 22:67-76
70. Kusunoki Y, Furuse K, Yamori S, et al. Randomized phase II study of vinorelbine (VRB) vs vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC): final results [abstract]. Proc Am Soc Clin Oncol 1995; 14:353
71. Yamamoto M, Ariyoshi Y, Hasegawa K, et al. Phase-I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients. Jpn J Cancel Chemother 1994; 21: 993-99
72. Kanzawa F, Nishio K, Kubota N, et al. Antitumor activities of a new indolecarbozole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res 1995; 55:2806-13
73. Sasaki Y, Tanigawara Y, Fujii H, et al. Phase I and pharmacology study of NB-506 [abstract]. Proc Am Soc Clin Oncol 1995; 14:172
74. Kamishohara M, Kawai H, Odagawa A, et al. Structure-antitumor activity relationship of semi-synthetic spikamycin analogues. J Antibiot 1993; 46:1439-46
75. Lee YS, Nishio K, Ogasawara H, et al. In vitro cytotoxicity of novel antitumor antibiotic, spikamycin derivative, in human lung cancer cell lines. Cancer Res 1995; 55:1075-79
76. Devita VT, Oliverio VT, Muggia FM, et al. The drug development program and clinical trial programs of Division of Cancer Treatment, National Cancer Institute. Cancer Clin Trials 1979; 2:195-216
77. Akinaga S, Nomura K, Gomi K, et al. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32:183-89
78. Akinaga S, Nomura K, Gomi K, et al. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 1994; 33:273-80
79. Kwokawa K, Ishida T, Nishio K, et al. V-glutamylcystein synthetase gene expression results in increased activity of the ATP-dependent glutathion S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 1995; 216:258-64
80. Dirix L, Catimel G, Koier I, et al. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. Anticancer Drugs 1995; 6:53-63
81. Dirix L, Catimel G, Verdonk R, et al. Phase I and pharmacokinetic study of KW-2149 given by 24 hour continuous infusion. Invest New Drugs 1995; 13:133-36
82. Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86:776-82